Licensing Agreement Sample Contracts

Xiangtian (Usa) Air Power Co., Ltd. – AGREEMENT ON KNOW-HOW SUB-LICENSE by PARTY a Luck Sky (Shen Zhen) Aerodynamic Electricity Limited and PARTY B Xianning Xiangtian Energy Holding Group Co., Ltd. September 30, 2018 Know-How Sub-Licensing Agreement (October 30th, 2018)

This Agreement on Know-how Sub-License (the "Agreement") is made as of September 30, 2018 between the following parties in the territory of People's Republic of China (the "PRC", exclusive of Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan Region for the purpose of this Agreement).

Centrexion Therapeutics Corp – Confidential Treatment Requested Centrexion Therapeutics Corporation AMENDMENT #1 TO PATENT ASSIGNMENT AND LICENSING AGREEMENT (October 19th, 2018)
Centrexion Therapeutics Corp – Confidential Treatment Requested Centrexion Therapeutics Corporation AMENDMENT #1 TO PATENT ASSIGNMENT AND LICENSING AGREEMENT (September 10th, 2018)
Centrexion Therapeutics Corp – Patent Assignment and Licensing Agreement (September 10th, 2018)
Trunity Holdings, Inc. – Licensing Agreement (August 16th, 2018)

This Sponsored Licensing Agreement ("Agreement") is entered into by True Nature Holding Inc., doing business ("TNTY") and (the "Healthcare Industry Provider, or "User"), effective on the date it is last signed by the Parties (the "Effective Date").

Disposition of a Unit of Product to a Third Party End User (The " Gross Sales Price "), After Deduction (If Not Already Deducted in the Amount Invoiced) of the Following Expenses Paid by the Selling Party for Such Product That Are Each Actually Incurred and Itemized on Such Invoice by the Selling Party: (I) Freight, Shipping, Transportation and Insurance Costs; (Ii) Discounts, in Reasonable Amounts That Are Customary in the Trade, That Are Actually Given to Buying Groups, Health Care Insurance Carriers, Chain Pharmacies, Mass Merchandisers, Staff Model HMOs, Pharmacy Benefit Managers, and Othe (August 8th, 2018)
Retrospettiva Inc – Licensing Agreement (May 24th, 2018)

This LICENSING AGREEMENT ("Agreement") is made effective as of this 15'" day of February, 2017_("Effective Date"), by and between AMMO, Inc., a Delaware corporation ("AMMO") with an office at 6402 East Thomas Rd, Scottsdale, AZ 85251, and Jeff Rann, an individual residing at 5420 County Road 531, Hondo, TX, 78861 ("JR").

Retrospettiva Inc – Licensing Agreement (May 24th, 2018)

This LICERNSING AGREEMENT ("Agreement") is made effective as of this 11th day of October, 2016 ("Effective Date"), by and between AMMO, Inc., a Delaware corporation ("AMMO") with an office at 6402 East Thomas Rd, Scottsdale , AZ 85251, and Jesse James, an individual residing at 12295 Trautwein Rd., Austin Texas 78737 ("JJ"), and, solely for the purposes of Section 7, Jesse James Firearms Unlimited, LLC, a Texas limited liability company having an address of 12295 Trautwein Rd., Austin Texas 78737 ("JJFU").

Nuvilex Inc – Third Amendment to Licensing Agreement (May 15th, 2018)

This Third Amendment to the Licensing Agreement ("Third Amendment") is effective on the date the parties have fully signed the Third Addendum ("Effective Date of the Third Amendment") and memorializes the agreement reached between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor") on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of 1 December 2014, as amended by the First Amendment to the Licensing Agreement dated as of June 30, 2015 and the Second Amendment to the Licensing Agreement dated as of 19 October 2015 (collectively, "Licensing Agreement"). Licensee and Licensor are referred to in this Third Amendment individually as a "Party" and collectively as the "Parties." Defined terms in the Licensing Agreement have the same meaning in this Third Amendment as they do in the Licensing Agreement.

Nuvilex Inc – Second Amendment to Licensing Agreement (May 15th, 2018)

This Second Amendment to the Licensing Agreement ("Second Amendment") is effective on the date the parties have fully signed the Second Amendment ("Effective Date of the Second Amendment") and memorializes an agreement reached between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte. Ltd. ("Licensor") on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of June 25, 2013, as amended by the First Amendment to the Licensing Agreement dated as of 24 June 2016 (collectively, "Licensing Agreement"). Licensee and Licensor are referred to in this Second Amendment individually as a "Party" and collectively as the "Parties." Defined terms in the Licensing Agreements have the same meaning in this Second Amendment as they do in the Licensing Agreement.

HYBRID Coating Technologies Inc. – Fourteenth Amendment to the Licensing Agreement Previously Entered Into (May 7th, 2018)

Nanotech Industries International Inc., a Nevada corporation (and a wholly owned subsidiary of Hybrid Coating Technologies Inc.)

Tapinator, Inc. – Games Development and Licensing Agreement (April 30th, 2018)

This Agreement (the "Agreement") is made by and among TapGames, a Pakistani Registered Firm as Partnership, of 14 D , L Block Gulberg 3 Lahore, Pakistan (hereinafter "TapGames" which expression shall be deemed to include successors in interest, legal heirs and assigns), Khurram Samad an individual who may receive Notice care of GeniTeam, House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan, Rizwan Yousuf an individual who may receive Notice care of GeniTeam, House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan, GenITeam, a Pakistani Corporation located at House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan and Tapinator, Inc., an American corporation duly registered and incorporated in the State of Delaware, having its office address at 110 West 40th St., Suite 1902 New York, NY, 10018 USA (hereinafter "Tapinator" which expression shall be deemed to include affiliates, successors in interest and permitted assigns).

Tapinator, Inc. – First Amendment to Games Development and Licensing Agreement (April 30th, 2018)

THIS FIRST AMENDMENT TO GAMES DEVELOPMENT AND LICENSING AGREEMENT (the "First Amendment") is entered into effective as of August 31, 2017 by and among TapGames, a Pakistani Registered Firm as Partnership, of 14 D , L Block Gulberg 3 Lahore, Pakistan (hereinafter "TapGames" which expression shall be deemed to include successors in interest, legal heirs and assigns), Khurram Samad an individual who may receive Notice care of GeniTeam, House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan, Rizwan Yousuf an individual who may receive Notice care of GeniTeam, House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan, GenITeam, a Pakistani Corporation located at House #14D, Block L, Main Ferozepur Road, Gulberg III, Lahore, Pakistan and Tapinator, Inc., an American corporation duly registered and incorporated in the State of Delaware, having its office address at 110 West 40th St., Suite 1902 New York, NY, 10018 USA (hereinafter "Tapinator" which expression sh

United States Commodity Index Funds Trust – Amended and Restated Licensing Agreement (April 24th, 2018)

This Amended and Restated Licensing Agreement ("Agreement") is made and entered into as of May 1, 2018 ("Effective Date"), by and between (i) SummerHaven Index Management, LLC ("SHIX"), a Delaware limited liability company with its principal place of business at 1266 East Main Street, Soundview Plaza, Fourth Floor, Stamford, CT 06902, (ii) United States Commodity Funds LLC ("USCF"), a Delaware limited liability company with its principal place of business at 1999 Harrison Street, Suite 1530, Oakland, California 94612, (iii) solely with respect to Section 3(g)(iii) of this Agreement, SummerHaven Investment Management, LLC ("SHIM"), a Delaware limited liability company with its principal place of business at 1266 East Main Street, Soundview Plaza, Fourth Floor, Stamford, CT 06902.

Ophthalix Inc – Third Amendment to Exclusive Distribution and Licensing Agreement (March 29th, 2018)

This Third Amendment (the "Third Amendment") is entered into on December 26, 2017 (the "Effective Date"), by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the "Licensor") and Wize Pharma Ltd., reg. no. 520033259, the former name of which is Star Night Technologies Ltd. (the "Licensee") (the Licensor and the Licensee shall be collectively referred to hereinafter as the "Parties").

Licensing Agreement (February 20th, 2018)

This Licensing Agreement (Agreement) is made effective as of January 19, 2018 (the Effective Date) by and between United Cannabis Corporation, (UCANN) and FLRish IP, LLC (Licensee). UCANN and Licensee may be referred to herein collectively as the Parties.

Prana Bio Nutrient Medicinals Supply, Distribution, and Licensing Agreement (February 20th, 2018)

This Supply, Distribution, and Licensing Agreement (Agreement) is made effective as of December 12, 2017 (the Effective Date) by and between United Cannabis Corporation, (UCANN) and Lasco Manufacturing Limited a company incorporated under the Companies Act and having its registered office at 27 1/2 Red Hills Road, in the parish of Saint Andrew, Jamaica (Licensee). UCANN and Licensee may be referred to herein collectively as the Parties.

Pineapple Express, Inc. – Licensing Agreement (January 23rd, 2018)

This Licensing Agreement (the " Agreement") is entered into and made effective as of May 26, 2017 (the "Effective Date") by and between Pineapple Express, Inc. and THC Industries, LLC (collectively the " Licensor " ) with a mailing address of _________,on the one hand, and The Hit Channel, Inc. (the "Licensee") with an address% Singh, Singh & Trauben, LLP, 400 S. Beverly Dr., Suite 240 , Beverly Hills, CA 90212, Attn: Simran Singh, Esq., on the other hand.

LICENSING AGREEMENT by and Among BLACK STALLION OIL & GAS, INC. A Corporation Incorporated in the State of Delaware, ACTIVE LAB INTERNATIONAL, INC. A Corporation Incorporated in the State of Wyoming Dated as of August 8, 2017 LICENSING AGREEMENT (September 22nd, 2017)
Neurokine Pharmaceuticals Inc. – Pivot - Altum Licensing Agreement (September 13th, 2017)

This EXCLUSIVE LICENSING AGREEMENT is made this 12th day of September 2017 (hereinafter the "Effective Date"), by and between PIVOT PHARMACEUTICALS INC., a corporation organized under the laws of British Columbia with an address c/o Alexander Holburn Beaudin & Lang LLP at 2700-700 West Georgia Street, Vancouver, British Columbia V7Y 1B8 (hereinafter "PIVOT") and ALTUM PHARMACEUTICALS INC., a corporation organized under the laws of British Columbia with an address c/o 1275 West 6th Street, Suite 300, Vancouver, BC V6C 1V5 (hereinafter "ALTUM"). PIVOT and ALTUM herein may be referred to individually as "Party" or together as "Parties."

Palatin Technologies, Inc. – Palatin Technologies Announces Signing of Licensing Agreement With Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories (September 7th, 2017)

CRANBURY, NJ - September 6, 2017 - Palatin Technologies, Inc. (NYSE MKT: PTN;"Palatin") announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the territories of mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Fosun Pharma is a leading Chinese healthcare provider with annual sales of more than $2 billion. Bremelanotide is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin previously announced positive Phase 3 results with bremelanotide for treating HSDD in premenopausal women. A New Drug Application (NDA) is anticipated to be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of cale

WOWI, Inc. – WOWI Inc Licensing Agreement (August 11th, 2017)

This License Agreement (this "Agreement" of this "License Agreement") is made and effective as of 7/1/2015 (the "Commencement Date") by and between:

Insys Therapeutics Inc. – Amendment Number One to the Amended and Restated Supply, Development & Exclusive Licensing Agreement (August 7th, 2017)

THIS AMENDMENT NUMBER ONE ("Amendment Number 1") to the AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT with an effective date of October 30, 2015 (the "A&R Agreement"), is hereby entered into as of April 6, 2017 with an effective date of January 1, 2017 ("Effective Date"), by and between INSYS MANUFACTURING, LLC, a Texas limited liability company, having its place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 ("PURCHASER") and APTARGROUP, INC., a Delaware corporation, having its place of business at 475 West Terra Cotta Avenue, Suite E, Crystal Lake, IL 60014-9695 ("SELLER").

Pacificorp Holdings Ltd. – ADDENDUM "A" Addendum to Licensing Agreement (July 31st, 2017)

This is an addendum dated 25 July, 2017 to a Licensing Agreement ("Agreement") dated and amended on June 1, 2017 wherein AGHWA, LLC, ("Licensor"), agrees to License and Cannabis Leaf, Inc. ("Licensee"), agrees to the following revised terms.

Ophthalix Inc – Addition to the Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product - Dated November 22, 2015 (July 27th, 2017)

Subject to Wize Pharma exercising the Option mentioned in the Amendment to Licensing Agreement dated November 22, 2015 section 3, The minimal sales in every country will be based on the formula described in the Appendix E of the Eyedrops for the USA document signed May 1, 2015, except if different terms are agreed in advance, in writing with Resdevco.

Ophthalix Inc – Amendment No. 2 to Exclusive Distribution and Licensing Agreement Between Wize Pharma Ltd. (Formerly Star Night Technologies Ltd) and Resdevco Ltd. (July 27th, 2017)

This Amendment (the "Amendment") refers to the Exclusive Distribution and Licensing Agreement between Wize Pharma Ltd. ( the "Licensee") and Resdevco Ltd. (the "Licensor") signed on, May 1, 2015 as amended on November 22, 2015 (the "Agreement") and is entered into on the Execution Date (us defined below).

Ophthalix Inc – Amendment 2 to Licensing Agreement - Ukraine Market (July 27th, 2017)

1.This Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco Ltd. and Wize Pharma (formerly: Star Night Technologies) signed on May 1, 2015 (hereinafter called the "Agreement") 2.Territory is extended to The Ukraine, therefore the term Territory refers to both the USA and the Ukraine markets. 3.If the Agreement is terminated for the USA Territory, this event will have no consequences on this Amendment with the original Agreement 4.The term "FDA" should be replaced by "Ministry of Health of Ukraine" throughout the Agreement 5.The r

Ophthalix Inc – Exclusive Distribution and Licensing Agreement (July 27th, 2017)
Ophthalix Inc – Appendix F to Exclusive Distribution and Licensing Agreement" Between Resdevco Ltd. And Wize Pharma Signed on May 1, 2015. This Appendix Replaces the Document of the Same Name Dated July 1, 2017 (July 27th, 2017)
Tesaro – Tesaro and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan (July 27th, 2017)

Takedas Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia

Ophthalix Inc – Second Addition to the Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product -- Dated November 22, 2015 (July 27th, 2017)
Ophthalix Inc – Amendment 1 to Licensing Agreement - Israeli Market (July 27th, 2017)
Ophthalix Inc – November 22, 2015 Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product (July 27th, 2017)

This Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco Ltd. And Wize Pharma Ltd (Star Night Technologies Ltd) signed on, May 1, 2015 (hereinafter called the "Agreement")

Ophthalix Inc – Appendix G. To the Exclusive Distribution and Licensing Agreement, Dated May 1, 2015 July 20, 2017 (July 27th, 2017)

Resdevco Ltd. hereby declares that all its patents and trade names related to the LO2A unit dose eye drops may be used by Wize Phanna Ltd./ Ocu Wize Ltd. in the territories to which the Exclusive Distribution and Licensing Agreement, dated May 1, 2015 is extended (at present Israel and the Ukraine) as long as the contract for those territories is valid

HYBRID Coating Technologies Inc. – Thirteenth Amendment to the Licensing Agreement Previously Entered Into (June 20th, 2017)

Nanotech Industries International Inc., a Nevada corporation (and a wholly owned subsidiary of Hybrid Coating Technologies Inc.)